Chemotherapy-induced Peripheral Neuropathy
Conditions
Keywords
Peripheral Nervous System Diseases, Oncologists
Brief summary
Chemotherapy induced peripheral neuropathy (CIPN) is one of the most deleterious adverse effect of neurotoxic anticancer drugs affecting up to 40% of patients. These neurotoxic anticancer agents include mainly: cisplatin (bronchopulmonary cancers), oxaliplatin (colorectal cancers), paclitaxel (breast cancers and bronchopulmonary cancers), docetaxel (breast cancers and bronchopulmonary cancers) and bortezomib (multiple myeloma). CIPN affects not only the quality of life of patients, it also has a major impact on oncology strategy, forcing oncologists to reduce dose-intensity, to stop an ongoing chemotherapy regimen and to change therapeutic strategies, with a risk of compromising patients' survival. There is no real preventive or curative treatment (except duloxetine) for CIPN and it is not known what is the practice of oncologists in France? However, it is essential to know the degree of sensitivity of oncologists to this problem and their practice. With this study, the investigators propose to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
Detailed description
This observational and cross-sectional study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand). French oncologist will be contacted by email thanks to the regional cancer networks. Answer to the survey will be done online.
Interventions
OTHERsurvey
to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
Sponsors
UFR de Pharmacie (Clermont-Ferrand)
University Hospital, Clermont-Ferrand
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Oncologist
Exclusion criteria
* pain physician
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment strategy for CIPN | at day 1 | Name of the drug used to treat CIPN and therapeutic adjustments, relay to a pain doctor and use of drugs) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Perception of safety of the treatments used to treat CIPN | at day 1 | Visual analogic scale: 0 unacceptable adverse effect - 100 acceptable adverse effects |
| Treatment strategy for CIPN prevention | at day 1 | Name of the drug used to prevent CIPN and therapeutic adjustments |
| Estimation by the oncologist of the percentage of patients affected by CIPN | at day 1 | Visual analogic scale: 0% - 100% of patients |
| Proportion of assessments of the CIPN severity performed by the oncologist using a specific questionnaire | at day 1 | yes / no (percentage) if yes name of the questionnaire |
| Proportion of CIPN assessments performed by the oncologist with a clinical examination | at day 1 | yes / no (percentage) |
| Proportion of CIPN assessments performed by a neurological examination (neurologist) | at day 1 | yes / no (percentage) |
| Perception of effectiveness of the treatments used | at day 1 | Visual analogic scale: 0 no efficacy - 100 maximal efficacy |
| Sex of oncologists | at day 1 | Male / female |
| Organ or system speciality of oncologists | at day 1 | name of speciality |
| Number of chemotherapy prescriptions | at day 1 | Number of chemotherapy |
| Types of neurotoxic anticancer drugs prescribed | at day 1 | Name of drugs |
| Working place | at day 1 | French region of practice and type of structure (public / private) |
| Age of oncologists | at day 1 | years |
Countries
France
Outcome results
None listed